CoChat

DYRK1A inhibitors for disease therapy: Current status and perspectives

Open access
Liu, Tong, Wang, Yuxi, Wang, Jiaxing, Ren, Changyu, Chen, Hao, Zhang, Jifa · 2022 · European Journal of Medicinal Chemistry
Cited by 105

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Dual-specificity tyrosine phosphorylation-regulated kinase 1 A (DYRK1A) is a conserved protein kinase that plays essential roles in various biological processes. It is located in the region q22.2 of chromosome 21, which is involved in the pathogenesis of Down syndrome (DS). Moreover, DYRK1A has been shown to promote the accumulation of amyloid beta (Aβ) peptides leading to gradual Tau hyperphosphorylation, which contributes to neurodegeneration. Additionally, alterations in the DRK1A expression are also associated with cancer and diabetes. Recent years have witnessed an explosive increase in the development of DYRK1A inhibitors. A variety of novel DYRK1A inhibitors have been reported as potential treatments for human diseases. In this review, the latest therapeutic potential of DYRK1A for different diseases and the novel DYRK1A inhibitors discoveries are summarized, guiding future inhibitor development and structural optimization.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejmech.2021.114062

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 105

Metadata

Authors
Liu, T., Wang, Y., Wang, J., Ren, C., Chen, H., & Zhang, J.
Venue
European Journal of Medicinal Chemistry
Publisher
Elsevier BV
Published
2022-02
Volume
229
Pages
114062
ISSN
0223-5234 (ISSN-L)
OpenAlex
W4200323989
Cited by
105
References
7
FWCI
8.35
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DYRK1A inhibitors for disease therapy: Current status and perspectives. https://app.cochat.ai/papers/10.1016/j.ejmech.2021.114062
The paper
Liu, T., Wang, Y., Wang, J., Ren, C., Chen, H., & Zhang, J. (2022). DYRK1A inhibitors for disease therapy: Current status and perspectives. European Journal of Medicinal Chemistry. https://doi.org/10.1016/j.ejmech.2021.114062

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.